Akero Therapeutics Inc.

AI Score

0

Unlock

21.85
-0.78 (-3.45%)
At close: Jan 14, 2025, 3:59 PM
22.38
2.43%
Pre-market Jan 15, 2025, 06:26 AM EST
undefined%
Bid 21.47
Market Cap 1.53B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.78
PE Ratio (ttm) -5.78
Forward PE n/a
Analyst Buy
Ask 22.87
Volume 1,041,577
Avg. Volume (20D) 641,716
Open 22.81
Previous Close 22.63
Day's Range 21.34 - 23.20
52-Week Range 15.32 - 37.00
Beta undefined

About AKRO

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2019
Employees 60
Stock Exchange NASDAQ
Ticker Symbol AKRO

Analyst Forecast

According to 8 analyst ratings, the average rating for AKRO stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 110.53% from the latest price.

Buy 87.50%
Hold 12.50%
Sell 0.00%
Stock Forecasts
10 months ago · Source
+11.72%
Akero Therapeutics shares are trading higher after... Unlock content with Pro Subscription